REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results and operational highlights. Listeners can register for the webcast to participate in the Q&A session. A replay will be available on the investor website.

News Market Reaction – RGNX

+5.54%

+5.54% Session move

In the trading session that priced this news, RGNX gained 5.54%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2024-financial-results-and-recent-operational-highlights-302132540.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO host the conference call to discuss first quarter 2024 financial results?

REGENXBIO will host the conference call on May 8, 2024.

What is the stock symbol of REGENXBIO?

The stock symbol of REGENXBIO is RGNX.

How can analysts participate in the question and answer session during the conference call?

Analysts can participate in the question and answer session by using the provided link.

Where can participants find a replay of the webcast after the conference call?

Participants can find a replay of the webcast on the company's investor website approximately two hours after the call's conclusion.